"rationale","uuid:ID","instanceType","id","versionIdentifier"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","ef18c453-8e29-42ce-9549-f67779ba32bc","StudyVersion","StudyVersion_1","2"
